Want to see XCUR full AI Analyst Report?
XCUR Stock Chart & Stats
$1.76
-$0.01(-0.57%)
At close: 4:00 PM EDT
$1.76
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$1.18 - $9.48
Previous Close$1.7
Volume19.01K
Average Volume (3M)23.77K
Market Cap
$9.36M
Enterprise Value$11.54
Total Cash (Recent Filing)$1.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding6,545,995
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEliminating debt reduces interest and refinancing pressure and gives Exicure a cleaner capital structure. This remains a durable relative strength, although the company still needs funding to support operations and development.
Reoriented Lead ProgramA focused lead program in stem cell mobilization gives Exicure a defined path to rebuild its pipeline after restructuring. Progress in multiple myeloma and sickle cell disease could create longer-term strategic value if development milestones are achieved.
Improved Governance OversightRefreshing the board with added independent oversight and a dedicated Compensation Committee may strengthen governance, accountability, and decision-making. These improvements can support execution and investor confidence over a multi-month horizon.
Bears Say
No Commercial RevenueThe absence of revenue indicates that Exicure has no meaningful commercial base to fund operations or validate its platform economically. Negative gross profit and continuing losses leave the business dependent on future development success or external financing.
Persistent Cash BurnSustained negative operating and free cash flow means Exicure is consuming capital rather than generating resources internally. Unless spending falls or new capital is secured, ongoing cash burn could constrain development activity and increase financing risk.
Equity Erosion And Capital DepletionSharp equity erosion reflects the cumulative impact of continued losses and leaves a thin capital cushion relative to ongoing needs. With total assets of about $11.4M and sharply negative returns on equity, financial resilience remains limited.
Exicure News
XCUR FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $1.18 and its highest was $9.48 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is $9.36M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Nov 12, 2026 which is in 84 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Aug 07, 2026. The company reported -$0.176 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,545,995 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -$0.176 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.37%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in XCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Technical Analysis
Ownership Overview
58.38% Insiders
0.92% Mutual Funds
<0.01% Other Institutional Investors
40.05% Public Companies and
Individual Investors